| ¿µ¹® | vaccination | ÇÑ±Û | ¿¹¹æÁ¢Á¾ |
|---|---|---|---|
| ¼³¸í | 1.ÀÎÀ§ÀûÀ¸·Î ´Éµ¿¸é¿ªÀ» ¼º¸³½ÃÄѼ °¨¿°¿¡ ´ëÇÑ ÀúÇ×·ÂÀ» ³ôÀ̱â À§ÇÏ¿© ¾àµ¶Èº´¿øÃ¼(»ý¹é½Å) ¶Ç´Â »ç±Õ, ºÒȰ¼º ȹé½Å µîÀ» Á¢Á¾ÇÏ´Â °ÍÀ» ¸»ÇÑ´Ù. ´çÃÊ Á¾µÎ´Â Á¨³Ê(Jenner)¿¡ ÀÇÇØ¼ ¹ß°ßµÈ ¸¶¸¶ ¿¹¹æ¹ý¿¡ °üÇÑ Á¢Á¾À» ÀǹÌÇßÀ¸³ª ÇöÀç¿¡´Â ³Î¸® °¨¿°ÁõÀ̳ª Àü¿°º´ÀÇ º´¿ø±Õ ±× ÀÚü°¡ ÀϺθ¦ Á¢Á¾Çؼ ºñ°¨¿°ÀÚ¸¦ ¸é¿ªÇÏ´Â °ÍÀ» ÀǹÌÇÑ´Ù. ¿¹¹æÁ¢Á¾À¸·Î Ç¥ÁØÈµÇ¾úÀ¸¸ç, Ç׿øÀ¸·Î¼ ¹é½ÅÀÌ »ç¿ëµÈ´Ù. ¿¹¹æÁ¢Á¾À¸·Î °¨¿°ÀÌ ¾ïÁ¦µÇÁö¸¸ ÇǺο¡ ³ªÅ¸³ª´Â ÀÌ»óÀ̳ª µÎµå·¯±â¸ð¾ç È«¹Ý µîÀÇ ÇǺιßÁøÀ̳ª ³ú¿° µîÀÇ ºÎÀÛ¿ëÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÁÖÀǸ¦ ¿äÇÑ´Ù. 2.¿¹¹æÁ¢Á¾¿¡ ¾²ÀÌ´Â Ç׿ø¿¡´Â Å©°Ô ³ª´©¾î ¼¼±Õ¼º Ç׿ø°ú ¹ÙÀÌ·¯½º¼º Ç׿øÀÌ Àִµ¥, ¼¼±Õ¼º Ç׿ø¿¡´Â »ç¸êµÈ Àüü ¼¼±Õ(¹éÀÏÇØ ¹é½Å µî), º´¿øÃ¼°¡ ü¿Ü·Î ¹èÃâÇÏ´Â µ¶¼Ò¸¦ ¸êµ¶ÇÑ º¯¼ºµ¶¼Ò(Åå¼ÒÀ̵å)(µðÇÁÅ׸®¾Æ-ÆÄ»ódz µî), µ¶·ÂÀ» ¾àȽÃŲ »ý¼¼±Õü(BCG µî)µîÀÌ ÀÖ°í, ¹ÙÀÌ·¯½º¼º Ç׿ø¿¡´Â »ý¾àµ¶ÈÇÑ °Í(¼Ò¾Æ¸¶ºñ)°ú »ç¸êµÈ ¹é½Å(ÀÎÇ÷翣ÀÚ) µîÀÌ Æ÷ÇԵȴÙ. Çѱ¹¿¡¼´Â Àü¿°º´ ¿¹¹æ¹ý¿¡ µÎâ-µðÇÁÅ׸®¾Æ-¹éÀÏÇØ-ÀåÆ¼Çª½º-ÄÝ·¹¶ó-ÆÄ»ódz-°áÇÙ µî Àϰö °³ Áúº´¿¡ °üÇÏ¿© Á¤±â ¿¹¹æÁ¢Á¾À» ½ÃÇàÇϵµ·Ï µÇ¾î ÀÖ´Ù. ¶Ç ´ëÇѼҾưúÇÐȸ¿¡¼´Â BCG-¼Ò¾Æ¸¶ºñ-µðÇÁÅ׸®¾Æ-¹éÀÏÇØ-ÆÄ»ódz-È«¿ª-À¯Ç༺±Í¹Ø»ù¿°(º¼°Å¸®)-dzÁø-ÀϺ»³ú¿° µî ¾ÆÈ© °³ ¿¹¹æÁ¢Á¾À» Á¤Çϰí ÀÖ´Ù. |
||
| ¿µ¹® | serum | ÇÑ±Û | Ç÷û |
|---|---|---|---|
| ¼³¸í | Ç÷¾×ÀÇ ¼ººÐ Áß °íÇü¼ººÐÀÎ Ç÷±¸¼¼Æ÷(ÀûÇ÷±¸, ¹éÇ÷±¸ µî), Ç÷¼ÒÆÇÀ» Á¦¿ÜÇÑ ºÎºÐÀ» Ç÷ÀåÀ̶ó°í Çϰí, Ç÷Àå¿¡¼ ¼¶À¯¼Ò¸¦ Á¦¿ÜÇÑ ºÎºÐÀ» Ç÷ûÀ̶ó°í ÇÑ´Ù. |
||
| ¿µ¹® | serum proteins | ÇÑ±Û | Ç÷û´Ü¹é |
|---|---|---|---|
| ¼³¸í | Ç÷û¿¡ ÀÖ´Â ´Ü¹éÁúµéÀ» ÃÑĪÇÏ´Â ¸»·Î, ¸é¿ª±Û·ÎºÒ¸°(¸é¿ªÇö»ó¿¡ °ü¿©ÇÏ´Â Ç×ü¸¦ Çü¼ºÇÔ), ¾ËºÎ¹Î, º¸Ã¼ ¹× ÀÀ°íÀÎÀÚ¿Í ¿©·¯ È¿¼ÒµéÀÌ ÀÌ¿¡ ¼ÓÇÑ´Ù. |
||
| ¿µ¹® | serum enzyme | ÇÑ±Û | Ç÷ûȿ¼Ò |
|---|---|---|---|
| ¼³¸í | Ç÷û ³»¿¡ Æ÷ÇԵǾî ÀÖ´Â ¿©·¯ °¡Áö È¿¼Ò¸¦ ÀÏÄ´ ¸»ÀÌ´Ù. |
||
| ¿µ¹® | hepatitis | ÇÑ±Û | °£¿° |
|---|---|---|---|
| ¼³¸í | °£¿¡ »ý±â´Â ¿°ÁõÀ» ÅëÆ²¾î À̸£´Â ¸». ¹ß¿-Ȳ´Þ-Àü½Å±ÇÅÂ-¼ÒÈ Àå¾ÖÀÇ Áõ»óÀ» º¸À̴µ¥, ÁÖµÈ ¿øÀÎÀº À½½Ä¹°°ú Ç÷¾×À» ÅëÇÑ ¹ÙÀÌ·¯½º °¨¿°ÀÌ¸ç ±× ¹Û¿¡ ¾à¹°, ¾ËÄÚ¿Ã, ¾Ë·¹¸£±â µîÀÌ ¿øÀÎÀÎ °Íµµ ÀÖ´Ù. ÀÌ °£¿°Àº ±× Áö¼Ó±â°£¿¡ µû¶ó¼ ±Þ¼º°£¿°°ú ¸¸¼º°£¿°À¸·Î ³ª´©´Âµ¥, ¸¸¼º°£¿°Àº 6°³¿ù ÀÌ»ó °£¿°ÀÌ Áö¼ÓµÇ´Â °æ¿ì¸¦ ¸»ÇÏ°í ±Þ¼º°£¿°Àº 6°³¿ù ÀÌ»ó Áö¼ÓÇÏÁö ¸øÇÏ´Â °æ¿ì¸¦ ¸»ÇÑ´Ù. ±Þ¼º°£¿°Àº ¸·¿¬ÇÑ ¸íĪÀ¸·Î¼, °£ÀÇ ±Þ¼º-½ÇÁú¼º »óÇØÀÇ °ÅÀÇ ÀüºÎ¸¦ Æ÷°ýÇÏ´Â ³ÐÀº °³³äÀÌÁö¸¸, ½ÇÁ¦´Â ¹ÙÀÌ·¯½ºÀÇ °¨¿°À¸·Î »ý±â´Â °£¿°ÀÌ ´ëºÎºÐÀÌ´Ù. ¹ÙÀÌ·¯½º¼º °£¿°Àº À¯Ç༱°£¿°(AÇü)°ú Ç÷û°£¿°(BÇü)ÀÇ µÎ Á¾·ù°¡ Àִµ¥, À̵éÀº ¸ðµÎ Àü¿°¼º ÁúȯÀÌÁö¸¸ °¨¿° °æ·Î´Â ´Ù¸£´Ù. °¨¿° °æ·Î·Î À¯Ç༱°£¿°¹ÙÀÌ·¯½º´Â Ç÷¾×-»ùâÀÚ¾×-´ëº¯ Áß¿¡¼ Áõ¸íµÇ¹Ç·Î Àü¿°µÈ ¹°-À½½ÄÀ» ÅëÇÏ¿© °æ±¸°¨¿°µÇ°Å³ª ȯÀÚ¿ÍÀÇ Á÷Á¢ Á¢ÃË¿¡ ÀÇÇØ¼ °¨¿°µÈ´Ù. Ç÷û°£¿°Àº ¿À·ÎÁö ºñ°æ±¸Àû °¨¿°À¸·Î ȯÀÚÀÇ Ç÷û, Ç÷¾×ÀÇ ÁÖ»ç, ȯÀÚÀÇ Ç÷¾×¿¡ °¨¿°µÈ ÁÖ»ç±â µîÀ¸·Î °¨¿°µÈ´Ù. Àẹ±â´Â À¯Ç༺°£¿°ÀÌ 2~6ÁÖ°£À̰í, Ç÷û °£¿°Àº 6ÁÖ~6°³¿ù °¡·® µÈ´Ù. Ç÷û°£¿°Àº À¯ÇàÀÇ °èÀý-¿¬·É°ú´Â °ü°è°¡ ¾øÀ¸³ª, À¯Ç༺°£¿°Àº ÁÖ·Î °¡À»¿¡¼ °Ü¿ï¿¡ °ÉÃÄ ¸¹°í û¼Ò³â¿¡ ¸¹´Ù. Áõ¼¼´Â ¹ßº´Çϱâ 1ÁÖÀÏ ÀüºÎÅÍ ¿Â¸öÀÌ ³ë°ïÇÏ°í ½Ä¿åÀÌ ¶³¾îÁö¸ç µÎÅëÀÌ ÀÖ°í »óº¹ºÎ¿¡ ºÒÄè°¨ÀÌ »ý±â´Âµ¥, À¯Ç༺°£¿°¿¡¼´Â Ȳ´ÞÀÌ ³ªÅ¸³ª±â Àü¿¡ ¹ß¿(38¡É ÀüÈÄ)ÀÌ ÀÖÀ» ¶§°¡ ¸¹°í ¼öÀÏ ÈÄ¿¡ ÇØ¿µÈ´Ù. ¶Ç, °üÀý-Ç㸮°¡ ¾ÆÇà ¶§µµ ÀÖ¾î óÀ½¿¡´Â °¨±â·Î ¿ÀÀÎÇÒ ¶§°¡ ¸¹´Ù. Ç÷û°£¿°Àº ÀÌ·¯ÇÑ Ãʱâ Áõ¼¼°¡ °¡º±°í ¼¼È÷ ¹ßº´ÇÏ´Â °ÍÀÌ ¸¹´Ù. ÁÖÁõ¼¼´Â À§ÀåÁõ¼¼¿Í Ȳ´ÞÀ̸ç, ½Ä¿åºÎÁø-±¸Åä-±¸¿ªÁú, »óº¹ºÎÀÇ µÐÅë µîÀÌ ÀϾ¸ç, ¹ßº´ ÈÄ 4~5ÀÏ¿¡ Ȳ´ÞÀÌ ³ªÅ¸³´Ù. Ȳ´ÞÀº 1ÁÖÀÏÀ» ÀüÈÄÇÏ¿© ÃÖ°í¿¡ À̸£¸ç, ±× ÈÄ 1°³¿ù »çÀÌ¿¡ ¾ø¾îÁö¸é¼ ´Ù¸¥ Áõ¼¼µµ ÁÁ¾ÆÁø´Ù. °æ°ú´Â ±Þ¼º°£¿°Àº ¾à 70%°¡ ´ë°³ 1~3°³¿ù À̳»¿¡ Ä¡À¯µÇÁö¸¸ »¡¸® Ä¡·áµÇÁö ¾Ê´Â °Í Áß 15%°¡ ¸¸¼º°£¿°À¸·Î ÀÌÇàÇϸç, ±× ÀϺδ °£°æÈÁõÀ¸·Î ÀÌÇàÇÑ´Ù. ±Þ¼º°£¿° Áß¿¡´Â ¶§·Î´Â 10ÀÏ À̳»¿¡ »ç¸ÁÇÏ´Â Àü°Ý¼º°£¿°À̶ó°í ÇÏ´Â °Íµµ ÀÖ´Ù. º´ÀÇ Àüü °æ°ú Áß È²´ÞÀÌ ³ªÅ¸³ªÁö ¾Ê´Â ¹«È²´Þ¼º °£¿°À̶ó°í ÇÏ´Â °Íµµ ÀÖ¾î. ¸¸¼º°£¿°À¸·Î ÀÌÇàÇÏ´Â °Í¿¡´Â ÀÌ ¹«È²´Þ¼ºÀÌ ¸¹Àº °æÇâÀÌ ÀÖ´Ù. Ç÷û°£¿°µµ ¸¸¼ºÈÇϱ⠽±´Ù. |
||
| AH | abdominal hysterectomy; absorptive hypercalciuria; accidental hypothermia; acetohexamide; acid hydro... |
|---|---|
| vacc | vaccination |
| VS | vaccination scar; vaccine serotype; vagal stimulation; vasospasm; venesection; ventricular septum; v... |
| ATS | Achard-Thiers syndrome; acid test solution; alpha-D-tocopherol acid succinate; American Thoracic Soc... |
| HS | Haber syndrome; half strength; hamstring; hand surgery; Hartmann solution; head sling; healthy subje... |
| PV | post vaccination |
|---|---|
| AIH | 1)autoimmune hepatitis |
| AAH | Acute alcoholic hepatitis |
| AH | Acute hepatitis |
| AH | Alcoholic hepatitis |
primary's area
| vaccination, hepatitis a | When immediate protection against hepatitis a (infectious hepatitis) is needed, immunoglobulins are used. Protection is effective only if given within 2 weeks of exposure and lasts but 2-4 months. Immunoglobulins can be used to protect household contacts of someone with acute viral hepatitis and travelers to regions with poor sanitation and high hepatitis a rates, when the traveler has to depart sooner than the vaccines can take effect (about 2 weeks). Travelers can receive the immunoglobulin and vaccine simultaneously and be protected immediately and for longer term. When immediate protection is not needed, hepatitis a vaccines are considered for individuals in high-risk settings, including frequent world travelers, sexually active individuals with multiple partners, homosexual men, individuals using illicit drugs, employees of daycare centres, and certain health care workers, and sewage workers. Two hepatitis a vaccines called havrix and vaqta are commercially available in the u.s. Both are highly effective and provide protection even after only one dose. Two doses are recommended for adults and 3 doses for children (under 18 years of age) to provide prolonged protection. (12 Dec 1998) |
|---|---|
| vaccination, hepatitis b | Hepatits B (hep B) vaccine gives prolonged protection, but 3 shots over a half year are usually required. In the u.s., all infants receive hep b vaccine. Two vaccines (engerix-b, and recombivax-hb) are available in the us. The first dose of hep b vaccine is frequently given while the newborn is in the hospital or at the first doctor visit following birth. The second dose is given about 30 days after the initial dose. A booster dose is performed approximately six months later. Babies born to mothers testing positive for hep b receive, in addition, hbig (hep b immune globulin) for prompt protection. Older children (11-12 years) are advised to receive a hep b booster as are adults in high-risk situations including healthcare workers, dentists, intimate and household contacts of patients with chronic hep b infection, male homosexuals, individuals with multiple sexual partners, dialysis patients, iv drug users, and recipients of repeated transfusions. Health care workers accidentally exposed to materials infected with hep b (such as needle sticks), and individuals with known sexual contact with hep b patients are available in the u.s. Both are highly effective and provide protection even after only one dose. Two doses are recommended for adults and 3 doses for children (under 18 years of age) to provide prolonged protection. Vaccination, hepatitis b: hepatits b (hep b) vaccine gives prolonged protection, but 3 shots over a half year are usually required. In the u.s., all infants receive hep b vaccine. Two vaccines (engerix-b, and recombivax-hb) are available in the us. The first dose of hep b vaccine is frequently given while the newborn is in the hospital or at the first doctor visit following birth. The second dose is given about 30 days after the initial dose. A booster dose is performed approximately six months later. Babies born to mothers testing positive for hep b receive, in addition, hbig (hep b immune globulin) for prompt protection. Older children (11-12 years) are advised to receive a hep b booster as are adults in high-risk situations including healthcare workers, dentists, intimate and household contacts of patients with chronic hep b infection, male homosexuals, individuals with multiple sexual partners, dialysis patients, iv drug users, and recipients of repeated transfusions. Health care workers accidentally exposed to materials infected with hep b (such as needle sticks), and individuals with known sexual contact with hep b patients are usually given both hbig and vaccine to provide immediate and long term protection. (12 Dec 1998) |
| vaccination, infectious hepatitis | See Vaccination, hepatitis a. (12 Dec 1998) |
| vaccineation, serum hepatitis | See Vaccination, hepatitis b. (12 Dec 1998) |
| serum hepatitis | <virology> A form of viral hepatitis, known as serum hepatitis, because it is commonly spread through contact with infected blood products (transfusion). May also be spread sexually or from mother to infant. Hepatitis B can cause a much more severe infection than hepatitis A and can occur as an asymptomatic carrier state, a chronic infection or as cirrhosis of the liver. Those at risk (IV drug abusers, health care workers, dialysis patients, transfusion recipients, homosexuals) should be immunised with hepatitis B vaccine. The virus is 42nm diameter, with an outer sheath enclosing inner 27nm core particle containing the circular viral DNA. Aggregates of the envelope proteins are found in plasma and are referred to as hepatitis B surface antigen (HBsAg, previously called Australia antigen). The virus can persist for long periods (and in asymptomatic carriers), association of integrated virus with hepatocellular carcinoma is now well established. (27 Sep 1997) |
| serum hepatitis virus | The type species of the genus orthohepadnavirus which causes human hepatitis b and is also apparently a causal agent in human hepatocellular carcinoma. The dane particle is an intact hepatitis virion, named after its discoverer. Non-infectious spherical and tubular particles are also seen in the serum. (12 Dec 1998) |
| immunization, serum hepatitis | See Immunization, hepatitis b. (12 Dec 1998) |
| equine serum hepatitis | <veterinary> An acute hepatic disease of the horse, often associated with prior administration of biological products; neurologic signs and jaundice are usually prominent signs; aetiology is unknown. Synonym: Theiler's disease. (05 Mar 2000) |
| vaccination | <procedure> The introduction of vaccine into the body for the purpose of inducing immunity. Coined originally to apply to the injection of smallpox vaccine, the term has come to mean any immunising procedure in which vaccine is injected. Origin: L. Vacca = cow (18 Nov 1997) |
| vaccination, anthrax | A series of six shots over six months and booster shots annually, the anthrax vaccine now in use in the usa was first developed in the 1950s and approved by the food and drug administration for general use in 1970. It is produced by the michigan biologic products institute of michigan's department of health and is given routinely to veterinarians and others working with livestock. In december, 1997 it was announced that all us military would receive the vaccine, as do the military in the uk and russia, the reason being concern that anthrax might be used in biologic warfare. (12 Dec 1998) |
| vaccination, chickenpox | This vaccine prevents the common disease known as chickenpox (varicella zoster). While chickenpox is often considered a trivial illness, it can cause significant lost time on the job and in school and have serious complications including ear infections, pneumonia, and infection of the rash with bacteria, inflammation of the brain (encephalitis) leading to difficulty with balance and coordination (cerebellar ataxia), damaged nerves (palsies), and reye's syndrome, a potentially fatal complication. The vaccination requires only one shot given at about a year of age. If an older person has not had chickenpox, the shot may be given at any time. There have been few significant reactions to the chickenpox vaccine. All children, except those with a compromised immune system, should have the vaccination. (12 Dec 1998) |
| vaccination, children's | In the United States, it is recommended that all children receive vaccination against: - hepatitis b - diphtheria, tetanus, pertussis - haemophilus influenzae type b (hib), poliovirus, measles, mumps, rubella, varicella zoster virus (chickenpox). Every child in the u.s. Should have these vaccinations except when there are special circumstances and the child's doctor advises specifically against a vaccination. (12 Dec 1998) |
| vaccination, dpt | DPT immunization protects from diphtheria, pertussis (whooping cough), and tetanus and is given in a series of 5 shots at 2, 4, 6, 18 months of age and 4-6 years of age. Thanks to vaccination programs, these diseases have become less common. However, there are still unvaccinated individuals capable of carrying and passing diphtheria and pertussis to others who are not vaccinated. Tetanus bacteria are prevalent in natural surroundings, such as contaminated soil. See also vaccination, dtap. (12 Dec 1998) |
| vaccination, dt | DT (diphtheria and tetanus) vaccine does not protect from pertussis and is usually reserved for individuals who have had a significant adverse reaction to a dpt shot or who have a personal or family history of a seizure disorder or brain disease (12 Dec 1998) |
| vaccination, dtap | Like DPT, DTaP protects from diphtheria, pertussis (whooping cough) and tetanus. Dtap is the same as dtp, except that it contains only acellular pertussis vaccine which is thought to cause fewer of the minor reactions associated with immunization and is also probably less likely to cause the more severe reactions occasionally seen following pertussis vaccination. Dtap is currently recommended only for the shots given at 18 months and 4-6 years of age. (12 Dec 1998) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|